Literature DB >> 19148833

Leptin and lipid metabolism in chronic kidney failure.

H Kastarinen1, Y A Kesäniemi, O Ukkola.   

Abstract

OBJECTIVE: In the general population, leptin has been associated with atherosclerosis and has been shown to interfere with lipoprotein profiles. Patients with chronic renal failure are at increased risk of cardiovascular disease and display alterations in both lipoprotein and leptin levels. The aim of this study was to investigate the relationship between leptin and the lipoprotein profile in non-dialyzed patients with chronic kidney disease (CKD).
MATERIAL AND METHODS: Leptin and lipid and lipoprotein concentrations were studied in 73 CKD patients and in 68 healthy controls in a cross-sectional case-control design.
RESULTS: The mean leptin levels were increased in the CKD patients (24.0 (SD 37.1) ng/mL) compared to those in controls (9.0 (SD 8.5) ng/mL) (p = 0.008). Also, the ratio between leptin levels and body mass index (leptin/BMI) was increased in CKD patients (mean 0.80 (SD 1.03)) compared to that in controls (0.31 (SD 0.24)) (p = 0.001). In linear regression analysis, leptin independently predicted total cholesterol and triglycerides in CKD patients (p = 0.010 and p = 0.001, respectively) and ratio between total and HDL cholesterol (Chol/HDL) in controls (p = 0.024). Furthermore, in CKD patients, the leptin/BMI predicted the variation in total cholesterol and triglycerides (p = 0.010 and p = 0.002, respectively).
CONCLUSIONS: Leptin concentrations and leptin/BMI were elevated in CKD patients compared to those in controls. Leptin levels in both study groups, and leptin/BMI in the CKD group, were associated with atherogenic lipid profiles, which may contribute to the elevated cardiovascular risk that has been linked to hyperleptinaemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148833     DOI: 10.1080/00365510802706645

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  6 in total

1.  Polymorphisms in LEP and NPY genes modify the response to soluble fibre Plantago ovata husk intake on cardiovascular risk biomarkers.

Authors:  Anna Crescenti; Rosa Solà; Rosa M Valls; Anna Anguera; Lluís Arola
Journal:  Genes Nutr       Date:  2012-06-06       Impact factor: 5.523

2.  Plasma Leptin in Patients at Intermediate to High Cardiovascular Risk With and Without Type 2 Diabetes Mellitus.

Authors:  Martina Montagnana; Cristiano Fava; Giovanni Targher; Massimo Franchini; Elisa Danese; Sara Bonafini; Angela De Cata; Gian Luca Salvagno; Orazio Ruzzenente; Gian Cesare Guidi; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2016-07-29       Impact factor: 2.352

Review 3.  Obesity and diabetic kidney disease.

Authors:  Christine Maric-Bilkan
Journal:  Med Clin North Am       Date:  2012-11-27       Impact factor: 5.456

4.  Longitudinal association between serum leptin concentration and glomerular filtration rate in humans.

Authors:  Claudio Pedone; Baback Roshanravan; Simone Scarlata; Kushang V Patel; Luigi Ferrucci; Raffaele Antonelli Incalzi
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

5.  Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway.

Authors:  Jin Joo Cha; Young Youl Hyun; Yi Hwa Jee; Mi Jin Lee; Kum Hyun Han; Young Sun Kang; Sang Youb Han; Dae Ryong Cha
Journal:  Kidney Res Clin Pract       Date:  2012-06-26

Review 6.  Epicardial Adipose Tissue, Adiponectin and Leptin: A Potential Source of Cardiovascular Risk in Chronic Kidney Disease.

Authors:  Luis D'Marco; Maria Jesús Puchades; Jose Luis Gorriz; Maria Romero-Parra; Marcos Lima-Martínez; Carlos Soto; Valmore Bermúdez; Paolo Raggi
Journal:  Int J Mol Sci       Date:  2020-02-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.